肿瘤细胞治疗研究
英文原题：Piggybacking toward Progress for CAR T-Cell Therapy in Prostate Cancer.
P-PSMA-101 是一款首创的、富集干细胞记忆 T 细胞的、靶向前列腺特异性膜抗原（PSMA）的嵌合抗原受体（CAR）T 疗法。
P-PSMA-101是一种首创疗法，采用富含干细胞记忆T细胞、靶向前列腺特异性膜抗原（PSMA）的嵌合抗原受体（CAR）T细胞。该细胞疗法在两例患者中显示出显著临床活性，但PSA下降≥50%（PSA50）应答总体较为温和。部分患者出现严重免疫效应相关毒性，但新型诱导型caspase 9（iCasp9）安全开关在很大程度上有效缓解了毒性。参见Slovin等人的相关文章，第3540页。
P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, prostate-specific membrane antigen (PSMA)-targeting chimeric antigen receptor (CAR) T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. Although severe immune effector-related toxicities were observed in some patients, a novel inducible caspase 9 (iCasp9) safety switch was largely effective in mitigating toxicity. See related article by Slovin et al., p. 3540.
MEMBER ACCOUNT
登录成功会直接打开下一页。
